Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr Scanlon on the Incidence, Management, and Physiologic Impact of IVC Tumor Thrombus in RCC

December 6th 2025

Lorraine Scanlon, MD, discusses IVC tumor thrombus in RCC, its management, and how relieving venous congestion may improve renal function and guide future care.

Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment

December 6th 2025

Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.

Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC

December 6th 2025

Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Cretostimogene Grenadenorepvec Shows Efficacy in Papillary-Only, BCG-Unresponsive NMIBC

December 6th 2025

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Gemcitabine Intravesical System Yields Low Rate of Radical Cystectomy in BCG-Unresponsive, High-Risk NMIBC

December 6th 2025

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Management of Peripheral Neuropathy Does Not Compromise Survival Benefit With Frontline Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

December 5th 2025

Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

December 5th 2025

Timothy D. Lyon, MD, discuss logistical and clinical challenges faced by patients with non–muscle-invasive bladder cancer who undergo intravesical therapy.

Meta Analyses Show Suboptimal Efficacy With BCG in Metachronous NMIBC

December 5th 2025

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC

December 5th 2025

Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

Gemcitabine Intravesical System Use Is Practical and Straightforward in NMIBC

December 4th 2025

Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.

Dr Bellmunt on Future Directions With ctDNA-Guided Immunotherapy in Urothelial Cancer

December 3rd 2025

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.

TARA-002 Intravesical Therapy Generates High CR Rate in BCG-Naive NMIBC With CIS

December 3rd 2025

Interim data from ADVANCED-2 show 6- and 12-month CR rates of 69.2% and 50%, respectively, with TARA-002 in this patient population.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Five Under 5: Top Oncology Videos for the Week of 11/23

November 30th 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Dr Bellmunt on Adjuvant Atezolizumab in Patients With MIBC Who Were ctDNA+ After Initial Testing

November 28th 2025

Joaquim Bellmunt, MD, PhD, discusses subgroup and safety data from the phase 3 IMvigor011 trial in patients with MIBC.

ctDNA Insights Stand at the Forefront of Data-Driven, Individualized MIBC Management

November 25th 2025

In a recent Peer Exchange, bladder cancer experts reviewed the current treatment paradigm for muscle-invasive bladder cancer (MIBC) and discussed updates from ESMO 2025.

FDA Grants Fast Track Designation to AVZO-103 for Urothelial Cancer After Prior Enfortumab Vedotin

November 24th 2025

The FDA granted fast track designation to AVZO-103 for urothelial cancer previously treated with enfortumab vedotin.

Five Under 5: Top Oncology Videos for the Week of 11/16

November 23rd 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.